Nanomerics - Pharmaceutical Nanotechnology

“Nanomerics uses leading know-how in pharmaceutical nanotechnology to overcome the limitations of current medicines and develop products that deliver patient benefit in areas of unmet medical need.”

Fighting Fit - Nanomerics featured in CBI Business Voice

moleculesIn the October edition of the CBI's  online publication 'Business Voice' journalist Dan Jellinek looks at how leading UK innovators contribute to the expanding UK life science sector. Nanomerics' CEO Prof Andreas Schatzlein describes how support from the EPSRC,  the Wellcome Trust, and Innovate UK has helped Nanomerics to translate scientific research into medicines which bring important patient benefits.

Nanomerics CEO Andreas Schatzlein presents at APS PharmSci Conference

Nanomercis has been selected to present at the SME Showcase Session at the annual APS PharmSci Conference 2014. The conference subtitled 'The Science of Medicines', held from the 8th – 10th September 2014 at the University of Hertfordshire De Havilland Campus, is the largest UK event for pharmaceutical scientists. Prof Schatzlein will give a brief update on the development of Nanomerics lead product NM0127, a novel therapy for the treatment of severe chronic pain to replace current morphine like opioids.  

 

Antibodies to the Brain - A High Impact Collaboration

Nanomerics is embarking on a new EPSRC funded collaborative research project with the Danish pharmaceutical company H Lundbeck, UCL, and Exeter University.  

LogosAs part of the new collaboration, the company aims to develop new and exciting ways to deliver antibodies to the brain, building on the molecular envelope technology Nanomerics has developed to deliver previously undeliverable drugs to the organ.
 

UCL’s School of Life and Medical Sciences Celebrates Enterprise Successes

UCL Enterprise publicationSpin-out Nanomerics and its founders were highlighted in UCL’s School of Life and Medical Sciences recently launched  'Enterprise' publication. The brochure, available here, celebrates recent success stories of translation of scientific knowledge. 

Nanomerics new patent granted in Japan

 Nanomerics is pleased to announce that a Notice of Allowance has been received on one of its key MET patents - Japanese Patent  JP5469458. Nanomerics' CEO, Dr Andreas Schatzlein says, "we are delighted with this notice of allowance from the Japanese Patent Office.  This further strengthen's our MET patent estate and enables us to work  in a major and lucrative market".

Nanomerics CSO becomes International Controlled Release Society (CRS) Fellow

CRS logoAt the 2013 Controlled Release Society Nanomerics CSO was nominated to the CRS College of Fellows.  The College of Fellows recognizes CRS members who have made outstanding contributions to the field of delivery science and technology over a minimum of 10 years.  Only 5 fellowships are awarded annually. 

Nanomerics CSO becomes Eminent Fellow of the Academy of Pharmaceutical Scientists

APSGB logoIn September 2013, Nanomerics CSO, Professor Ijeoma Florence Uchegbu became an Eminent Fellow of the UK's Academy of Pharmaceutical Sciences.  The Eminent Fellowships are awarded based on a significant contribution in the pharmaceutical sciences.  
 
MET Fibrous Hydrogel
MET Fibrous Hydrogel
Subscribe to Nanomerics RSS